Versant Ventures Announces Launch of Dayra Therapeutics With Foundational Biogen Partnership
– Startup emerges from Versant's Frontier Discovery Engine with over $70 million in capital to develop oral macrocyclic peptides – Biogen and Dayra partnership will identify, validate and optimize oral macrocycle candidates for high-priority immunological tar
(Financial Post, 2025-11-24T12:37:47Z)